134 related articles for article (PubMed ID: 11335721)
1. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.
Ikuta M; Kamata K; Fukasawa K; Honma T; Machida T; Hirai H; Suzuki-Takahashi I; Hayama T; Nishimura S
J Biol Chem; 2001 Jul; 276(29):27548-54. PubMed ID: 11335721
[TBL] [Abstract][Full Text] [Related]
2. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
3. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
5. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
[TBL] [Abstract][Full Text] [Related]
6. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4.
Blain SW; Montalvo E; Massagué J
J Biol Chem; 1997 Oct; 272(41):25863-72. PubMed ID: 9325318
[TBL] [Abstract][Full Text] [Related]
7. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
Honma T; Hayashi K; Aoyama T; Hashimoto N; Machida T; Fukasawa K; Iwama T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Iwasawa Y; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4615-27. PubMed ID: 11741479
[TBL] [Abstract][Full Text] [Related]
8. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
11. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
[TBL] [Abstract][Full Text] [Related]
12. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
13. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
Calbó J; Serna C; Garriga J; Graña X; Mazo A
Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
Jeffrey PD; Tong L; Pavletich NP
Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
[TBL] [Abstract][Full Text] [Related]
17. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
18. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
[TBL] [Abstract][Full Text] [Related]
19. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
